Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 18/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13729718 | 1.00 | NAMPT (0.53) | NAMPTLMNASMN1; SMN2 | |
| SCHEMBL2919182 | 0.87 | NAMPT (0.48) | NAMPT | |
| SCHEMBL2923272 | 0.86 | NAMPT (0.47) | NAMPT | |
| SCHEMBL2915271 | 0.81 | NAMPT (0.46) | NAMPT | |
| SCHEMBL2924391 | 0.80 | CCNA2 (0.55) | NAMPT | |
| SCHEMBL2914576 | 0.78 | CCNA2 (0.55) | NAMPT | |
| SCHEMBL2914968 | 0.77 | CCNA2 (0.47) | NAMPT | |
| SCHEMBL2920224 | 0.77 | MAPT (0.46) | LMNASMN1; SMN2 | |
| SCHEMBL2924284 | 0.77 | MAPT (0.46) | LMNASMN1; SMN2 | |
| SCHEMBL2914036 | 0.76 | HDAC1 (0.43) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169209-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2015-10-27 | — | — | US | claimed |
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2014-09-18 | — | — | US | claimed |
| WO-2012150952-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2012-11-08 | — | — | WO | claimed |
| US-9169209-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2014-09-18 | — | — | US | disclosed |
| WO-2012150952-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NAPRT | NAMPT 1/4885LMNA 1255/4885SMN1; SMN2 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.